Computational drug repositioning of bortezomib to reverse metastatic effect of GALNT14 in lung cancer
O.-S. Kwon, H. Lee, H.-J. Kong, J. E. Park, W. Lee, S. Kang, M. Kim, W. Kim, H.-J. Cha
This study uses in silico drug repositioning to identify bortezomib as an inhibitor of GALNT14-driven lung cancer metastasis, validated through in vitro and in vivo experiments.
bioRxiv · Aug 17, 2018Pharmacology & Toxicology